Amarin Corporation PLC (NASDAQ:AMRN) – Equities research analysts at Jefferies Group raised their Q3 2017 earnings estimates for shares of Amarin Corporation PLC in a report issued on Monday. Jefferies Group analyst M. Andrews now expects that the biopharmaceutical company will post earnings per share of ($0.05) for the quarter, up from their prior estimate of ($0.06). Jefferies Group currently has a “Buy” rating and a $7.00 target price on the stock. Jefferies Group also issued estimates for Amarin Corporation PLC’s FY2017 earnings at ($0.22) EPS.

Amarin Corporation PLC (NASDAQ:AMRN) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.06) by $0.01. The company had revenue of $44.95 million during the quarter, compared to analysts’ expectations of $40.35 million. During the same quarter in the prior year, the business posted ($0.07) earnings per share. The company’s revenue was up 37.0% compared to the same quarter last year.

ILLEGAL ACTIVITY NOTICE: “Jefferies Group Weighs in on Amarin Corporation PLC’s Q3 2017 Earnings (AMRN)” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/11/jefferies-group-weighs-in-on-amarin-corporation-plcs-q3-2017-earnings-amrn.html.

Several other brokerages have also recently issued reports on AMRN. BidaskClub upgraded Amarin Corporation PLC from a “buy” rating to a “strong-buy” rating in a research note on Thursday, July 6th. Zacks Investment Research upgraded Amarin Corporation PLC from a “sell” rating to a “hold” rating in a research note on Monday, July 3rd. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Amarin Corporation PLC in a research note on Thursday, August 3rd. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $10.00 price objective on shares of Amarin Corporation PLC in a research note on Tuesday, September 26th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $7.20.

Amarin Corporation PLC (NASDAQ:AMRN) opened at 3.46 on Wednesday. Amarin Corporation PLC has a one year low of $2.75 and a one year high of $4.47. The stock’s market capitalization is $936.94 million. The stock has a 50 day moving average price of $3.30 and a 200-day moving average price of $3.33.

A number of institutional investors have recently bought and sold shares of AMRN. Wells Fargo & Company MN raised its stake in Amarin Corporation PLC by 4.8% in the first quarter. Wells Fargo & Company MN now owns 32,801 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 1,500 shares in the last quarter. Ameriprise Financial Inc. raised its stake in Amarin Corporation PLC by 0.9% in the first quarter. Ameriprise Financial Inc. now owns 395,769 shares of the biopharmaceutical company’s stock valued at $1,266,000 after buying an additional 3,413 shares in the last quarter. Raymond James Financial Services Advisors Inc. raised its stake in Amarin Corporation PLC by 1.4% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 143,650 shares of the biopharmaceutical company’s stock valued at $460,000 after buying an additional 2,050 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Amarin Corporation PLC by 27.1% in the first quarter. JPMorgan Chase & Co. now owns 35,590 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 7,580 shares in the last quarter. Finally, California Public Employees Retirement System raised its stake in Amarin Corporation PLC by 13.3% in the first quarter. California Public Employees Retirement System now owns 533,300 shares of the biopharmaceutical company’s stock valued at $1,707,000 after buying an additional 62,800 shares in the last quarter. Institutional investors own 37.76% of the company’s stock.

In other Amarin Corporation PLC news, insider Steven B. Ketchum sold 63,479 shares of the firm’s stock in a transaction on Thursday, October 5th. The stock was sold at an average price of $3.48, for a total value of $220,906.92. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 3.72% of the stock is owned by company insiders.

Amarin Corporation PLC Company Profile

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Earnings History and Estimates for Amarin Corporation PLC (NASDAQ:AMRN)

Receive News & Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.